Mahmood Salesi

Mahmood Salesi

Auto-generated profile, based on publicly available information

Mahmood Salesi

Chemical Injuries Research Center, Systems biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in International Journal of Occupational Safety and Ergonomics
Verified
Journal Article
Closed access
HKHajiomid Kalteh
Hajiomid Kalteh
SMSeyyed Bagher Moetazavi
Seyyed Bagher Moetazavi
AFAlhani Fatemeh
Alhani Fatemeh
MSMahmood Salesi
Mahmood Salesi
Introduction: It is known that there is a close relationship between safety culture and safety climate and safety performance. However, this relationship is somewhat unclear, due to different attitudes toward the safety culture and safety climate and the use of various tools for their evaluation, and various measures of safety performance. Methods: In this study, articles published in English from 2005 to 2017 were selected from various databases. Then, certain journals in the field of safety were specifically searched using the keywords “safety and safety performance”, “safety climate and safety performance”, “safety culture and safety performance”, “safety climate and safety outcome”, “safety culture and safety outcome”, “safety culture and injury and fatalities”, and “safety climate and injuries and fatalities”. Results: In the current paper, the role of safety culture and safety climate in improving safety performance was evaluated in 31 selected studies. It seems that reactive criteria and safety compliance is more consistent with safety climate and safety culture. Conclusions: The findings emphasized that increasing the level of safety climate and safety culture could be effective in reducing incidents and improving safety performance indicators.

11 November 2014 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
RRamezan Ali Ataee
Ramezan Ali Ataee
SHSamira Habibian
Samira Habibian
AMAli Mehrabi-Tavana
Ali Mehrabi-Tavana
ZAZyanab Ahmadi
Zyanab Ahmadi
NJNematollah Jonaidi
Nematollah Jonaidi
MSMahmood Salesi
Mahmood Salesi
In the context of growing health concerns over antibiotic resistance, the evaluation of the minimum inhibitory concentration (MIC) of vancomycin for Streptococcus pneumoniae (S. pneumoniae) strains resistant to ceftazidime becomes important for guiding health policy makers. The aim of this study was to determine vancomycin MIC of ceftazidime resistant S. pneumoniae strains. Fifty identified serotypes of ceftazidime resistant S. pneumoniae strains were included in the study. The vancomycin MIC of the above mentioned bacteria was determined based on the 0.5 McFarland standards, by using a microdilution broth and the Etest method. The results showed that out of 50 ceftazidime resistant strains of S. pneumoniae, 46 strains (92%) have shown a vancomycin MIC ≤0.19 − 0.1.5 μg/ml and only four strains (8%) have shown a vancomycin MIC equal to 1.5 μg/ml and the related maximum zone of inhibition was of 10 millimeter diameters. The results of this investigation point out the emergence of S. pneumoniae strains with a vancomycin MIC ≥1.5 μg/ml, which were resistant to ceftazidime. This finding uncovers a major health concern: a vancomycin MIC higher than 1.5 μg/ml and maximum zone of inhibition of only 10 millimeter. These findings represent an important warning for health authorities globally, concerning the treatment of patients, as the occurrence of S. pneumoniae strains with decreased vancomycin susceptibility has been demonstrated.

3 November 2022 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
MAMasoud Arabfard
Masoud Arabfard
MSMahmood Salesi
Mahmood Salesi
YNYazdan Hassani Nourian
Yazdan Hassani Nourian
IAIman Arabipour
Iman Arabipour
AMAliMohammad Ali Maddi
AliMohammad Ali Maddi
MOMina Ohadi
Mina Ohadi
Background: While of predominant abundance across vertebrate genomes and significant biological implications, the relevance of short tandem repeats (STRs) (also known as microsatellites) to speciation remains largely elusive and attributed to random coincidence for the most part. Here we collected data on the whole-genome abundance of mono-, di-, and trinucleotide STRs in nine species, encompassing rodents and primates, including rat, mouse, olive baboon, gelada, macaque, gorilla, chimpanzee, bonobo, and human. The collected data were used to analyze hierarchical clustering of the STR abundances in the selected species. Results: We found massive differential STR abundances between the rodent and primate orders. In addition, while numerous STRs had random abundance across the nine selected species, the global abundance conformed to three consistent < clusters>, as follows: , , and , which coincided with the phylogenetic distances of the selected species (p < 4E-05). Exceptionally, in the trinucleotide STR compartment, human was significantly distant from all other species. Conclusion: Based on hierarchical clustering, we propose that the global abundance of STRs is non-random in rodents and primates, and probably had a determining impact on the speciation of the two orders. We also propose the STRs and STR lengths, which predominantly conformed to the phylogeny of the selected species, exemplified by (t)10, (ct)6, and (taa4). Phylogenetic and experimental platforms are warranted to further examine the observed patterns and the biological mechanisms associated with those STRs.

4 January 2022 in EXCLI Journal
Verified
Journal Article
Open access
FRFarshid Rahimibashar
Farshid Rahimibashar
AMAndrew C. Miller
Andrew C. Miller
MSMahmood Salesi
Mahmood Salesi
MBMotahareh Bagheri
Motahareh Bagheri
AVAmir Vahedian-Azimi
Amir Vahedian-Azimi
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
A retrospective secondary analysis of 4,200 patients was collected from two academic medical centers. Delirium was assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) in all patients. Univariate and multivariate Cox models, logistic regression analysis, and Chi-square Automatic Interaction Detector (CHAID) decision tree modeling were used to explore delirium risk factors. Increased delirium risk was associated with exposed only to artificial light (AL) hazard ratio (HR) 1.84 (95 % CI: 1.66-2.044, P8 hours per 8-hour shift) 1.18 (95 % CI: 1.048-1.338, P=0.007). Delirium incidence was inversely associated with greater family engagement 0.092 (95 % CI: 0.014-0.596, P=0.012), low staff burnout and anticipated turnover scores 0.093 (95 % CI: 0.014-0.600, P=0.013), non-ICU length-of-stay (LOS)<15 days 0.725 (95 % CI: 0.655-0.804, P<0.001), and ICU LOS ≤15 days 0.509 (95 % CI: 0.456-0.567, P<0.001). CHAID modeling indicated that AL exposure and age 15 and natural light (NL) exposure were associated with moderate risk, and female sex was associated with low risk. More rapid time to delirium onset correlated with baseline sleep disturbance (P=0.049), high nursing care requirements (P=0.019), and prolonged ICU and non-ICU hospital LOS (P65 years (HR 2.198; 95 % CI: 1.101-4.388, P=0.026) and high nursing care requirements (HR 1.978, 95 % CI: 1.096-3.569), with CHAID modeling identifying AL exposure (P65 years (P=0.032) as predictive variables. Development of ICU delirium correlated with application of physical restraints, high nursing care requirements, prolonged ICU and non-ICU LOS, exposure exclusively to AL (rather than natural), less family engagement, and greater staff burnout and anticipated turnover scores. ICU delirium occurred more rapidly in patients with baseline sleep disturbance, and recurrence correlated with the presence of delirium on ICU admission, exclusive AL exposure, and high nursing care requirements.

25 October 2017 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
KKKhosro Keshavarz
Khosro Keshavarz
FLFarhad Hosseinzadeh Lotfi
Farhad Hosseinzadeh Lotfi
ESEhsan Sanati
Ehsan Sanati
MSMahmood Salesi
Mahmood Salesi
AHAmir Hashemi-Meshkini
Amir Hashemi-Meshkini
SNShekoufeh Nikfar
Shekoufeh Nikfar
Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as "linagliptin", "type 2 diabetes mellitus", "sitagliptin" and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-analysis was used to conduct a systematic comparison between the two studied drugs. This network meta-analysis included 32 studies (Linagliptin vs PLB: n = 8, Sitagliptin vs PLB: n = 13, Linagliptin + MET vs PLB + MET: n = 4, and Sitagliptin + MET vs PLB + MET: n = 7) and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change from baseline, percentage of patients achieving HbA1c 0.05). The results showed that the efficacy of the two drug regimens was the same. Based on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin, in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use of these two drugs depends on their availability and cost. Graphical abstract of the network meta-analysis performed to evaluate the alternatives under the study.

7 August 2024 in IJC Heart & Vasculature
Verified
Journal Article
Open access
YAYousef Jafari Abarghan
Yousef Jafari Abarghan
MHMohammad Heiat
Mohammad Heiat
AJAbolfazl Jahangirl
Abolfazl Jahangirl
MPMohammad Hossein Peypar
Mohammad Hossein Peypar
MAMahdi Abdorrashidi
Mahdi Abdorrashidi
HSHamid Sedighian
Hamid Sedighian
Monoclonal antibodies (mAbs) are currently under investigation as a potential therapeutic option for COVID-19. Clinical trials are examining their efficacy in lowering mortality rates and the requirement for mechanical ventilation (MV). It is necessary to conduct a thorough examination of current randomized controlled trials (RCTs) in order to provide more definitive evidence on their effectiveness for COVID-19 patients. This meta-analysis aims to analyze RCT results on the impact of three mAbs (Anakinra, Sarilumab, Tocilizumab) on COVID-19 patient outcomes. The meta-analysis was conducted in accordance with the PRISMA guidelines. Eligible RCTs were conducted to evaluate the effectiveness of three mAbs in treating patients with COVID-19. These trials were identified by searching various databases up to April 1, 2024. In total, this meta-analysis incorporated 19 trials with a total of 8097 patients. Pooled relative risk and studies' heterogeneity were assessed by statistical analysis, which involved the use of fixed effects models and subgroup analysis. The administration of mAbs (Tocilizumab, Sarilumab, and Anakinra) showed various results in the management of COVID-19 patients. While the overall pooled data did not reveal a significant reduction in the need for MV, the study found that the use of mAbs was associated with a decreased risk of clinical worsening (pooled relative risk: 0.75, 95 % CI [0.59, 0.94], p = 0.01) and an increased probability of discharging COVID-19 patients by day 28 or 29 (pooled relative risk: 1.17, 95 % CI [1.10, 1.26]). Notably, the subgroup analysis revealed that Tocilizumab had a significant effect in reducing the risk of clinical worsening compared to Sarilumab. Additionally, the analysis of mortality outcomes indicated that the administration of mAbs had the potential to decrease the overall risk of mortality over time (pooled RR: 0.90, 95 % CI [0.83, 0.97], p = 0.01). In summary, our meta-analysis suggests that mAbs, particularly Tocilizumab, may play a valuable role in managing COVID-19 by reducing the risk of clinical worsening, improving hospital discharge rates, and decreasing mortality.